FIL Ltd Reduces Position in Spark Therapeutics Inc (NASDAQ:ONCE)

FIL Ltd trimmed its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 6.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 93,057 shares of the biotechnology company’s stock after selling 6,308 shares during the quarter. FIL Ltd’s holdings in Spark Therapeutics were worth $10,597,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ONCE. Bank of Montreal Can lifted its stake in Spark Therapeutics by 84.8% during the fourth quarter. Bank of Montreal Can now owns 6,011 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 2,758 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Spark Therapeutics by 16.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 485 shares in the last quarter. Rhumbline Advisers lifted its position in Spark Therapeutics by 47.7% during the 4th quarter. Rhumbline Advisers now owns 42,372 shares of the biotechnology company’s stock worth $1,658,000 after buying an additional 13,686 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Spark Therapeutics by 7.0% during the 4th quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 313 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in Spark Therapeutics by 3.2% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 17,696 shares of the biotechnology company’s stock valued at $693,000 after buying an additional 546 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on ONCE. William Blair downgraded shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 7th. Jefferies Financial Group downgraded shares of Spark Therapeutics from a “buy” rating to a “hold” rating and lifted their target price for the stock from $85.00 to $114.50 in a research note on Tuesday, February 26th. Sanford C. Bernstein lowered shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $113.48 target price for the company. in a research report on Tuesday, February 26th. Zacks Investment Research upgraded shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 30th. Finally, Raymond James downgraded shares of Spark Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, February 25th. One analyst has rated the stock with a sell rating, seventeen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $78.45.

Shares of NASDAQ:ONCE opened at $99.98 on Wednesday. Spark Therapeutics Inc has a 12-month low of $34.53 and a 12-month high of $114.20. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of -47.38 and a beta of 2.28. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.94 and a quick ratio of 5.59.

COPYRIGHT VIOLATION NOTICE: “FIL Ltd Reduces Position in Spark Therapeutics Inc (NASDAQ:ONCE)” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2019/06/12/fil-ltd-reduces-position-in-spark-therapeutics-inc-nasdaqonce.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Read More: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.